The development of flavivirus vaccines

African Journal of Biotechnology

Volumn 9, Issue 4, 2010, Pages 409-415

  Pulmanausahakul, Rojjanaporn ^a   Khakpoor, Atefeh ^a   Smith, Duncan R ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Attenuation; Encephalitis; Fever; Flavivirus; Hemorrhagic; Vaccine

Indexed keywords

DENGUE VACCINE; DNA VACCINE; FLAVIVIRUS VACCINE; FRENCH NEUROTROPIC VACCINE; INACTIVATED VIRUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; JAPANESE ENCEPHALITIS VIRUS E PROTEIN; JAPANESE ENCEPHALITIS VIRUS NS1 PROTEIN; JAPANESE ENCEPHALITIS VIRUS NS2B PROTEIN; JAPANESE ENCEPHALITIS VIRUS NS5 PROTEIN; LIVE VACCINE; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 5; PDK 53 PROTEIN; PRM PROTEIN; RECOMBINANT VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TRUNCATED 3 PROTEIN; TRUNCATED E PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; WEST NILE VACCINE; WN 02; YELLOW FEVER 17D 204 VACCINE; YELLOW FEVER 17D VACCINE; YELLOW FEVER 17DD VACCINE; YELLOW FEVER VACCINE;

CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG WITHDRAWAL; FLAVIVIRUS; HUMAN; IMMUNITY; IMMUNIZATION; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS ENCEPHALITIS; VIRUS INFECTION; VISCEROTROPIC DISEASE; WEST NILE FLAVIVIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

FLAVIVIRUS; IXODIDA; JAPANESE ENCEPHALITIS VIRUS;

EID: 76649134126     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Aleshin SE, Timofeev AV, Khoretonenko MV, Zakharova LG, Pashvykina GV, Stephenson JR, Shneider AM, Altstein AD (2005). Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein. BMC Microbiol 5: 45.
2. Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, Monath TP (2004). ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78(22): 12497-12507.
3. Barnett ED (2007). Yellow fever: epidemiology and prevention. Clin. Infect. Dis. 44(6): 850-856.
4. Barrett AD (1997). Japanese encephalitis and dengue vaccines. Biologicals, 25(1): 27-34.
5. Barrett AD, Teuwen DE (2009). Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21(3): 308-313.
6. Barrett PN, Schober-Bendixen S, Ehrlich HJ (2003). History of TBE vaccines. Vaccine 21 Suppl 1: S41-49.
7. Burchard GD, Caumes E, Connor BA, Freedman DO, Jelinek T, Jong EC, von Sonnenburg F, Steffen R, Tsai TF, Wilder-Smith A, Zuckerman J (2009). Expert opinion on vaccination of travelers against Japanese encephalitis. J. Travel Med. 16(3): 204-216.
8. CDC (2003). Epidemic/Epizootic West Nile Virus in the United States: Guidelines for Surveillance, Prevention, and Control. http://wwwcdcgov/ncidod/ dvbid/westnile/ resources/wnv-guidelines-aug-2003pdf.
9. Chang GJ, Hunt AR, Davis B (2000). A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Virol. 74(9): 4244-4252.
10. Chu JH, Chiang CC, Ng ML (2007). Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 178(5): 2699-2705.
11. Dauphin G, Zientara S (2007). West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 25(30): 5563-5576.
12. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F (2005). Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 191(2): 207-214.
13. dos Santos CN, Post PR, Carvalho R, Ferreira, II, Rice CM, Galler R (1995). Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 35(1): 35-41.
14. Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, Khanna N (2008). An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 79(3): 353-363.
15. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, Mune M, Rosario D, Valdes K, Vazquez S, Martinez R, Serrano T, Paez J, Espinosa R, Pumariega T, Guillen G (2003). Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am. J. Trop. Med. Hyg. 69(2): 129-134.
16. Hall RA, Khromykh AA (2007). ChimeriVax-West Nile vaccine. Curr. Opin. Mol. Ther. 9(5): 498-504.
17. Kaur R, Vrati S (2003). Development of a recombinant vaccine against Japanese encephalitis. J. Neurovirol. 9(4): 421-431.
18. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K (2009). IC51 Japanese encephalitis vaccine. Expert. Opin. Biol. Ther. 9(7): 921-931.
19. Konishi E, Pincus S, Fonseca BA, Shope RE, Paoletti E, Mason PW (1991). Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology, 185(1): 401-410.
20. Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, Mason PW (1992). A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology, 190(1): 454-458.
21. Konishi E, Yamaoka M, Khin Sane W, Kurane I, Takada K, Mason PW (1999). The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol. 73(7): 5527-5534.
22. Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Lien SP, Yueh A, Hsiao KN, Lai LW, Liu FC, Chong P, Chen HW (2009). A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11(2): 288-295.
23. Leonova GN, Ternovoi VA, Pavlenko EV, Maistrovskaya OS, Protopopova EV, Loktev VB (2007). Evaluation of vaccine Encepur Adult for induction of human neutralizing antibodies against recent Far Eastern subtype strains of tick-borne encephalitis virus. Vaccine, 25(5): 895-901.
24. Liang JJ, Liao CL, Liao JT, Lee YL, Lin YL (2009). A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability. Vaccine, 27(21): 2746-2754.
25. Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, Martyak T, Gilson L, Coller BA, Leung J, Watts DM, Tesh RB, Siirin M, Travassos da Rosa A, Humphreys T, Weeks-Levy C (2007). Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine, 25(3): 414-423.
26. Lin YL, Chen LK, Liao CL, Yeh CT, Ma SH, Chen JL, Huang YL, Chen SS, Chiang HY (1998). DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J. Virol. 72(1): 191-200.
27. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL (2004). Dengue viral infections. Postgrad. Med. J. 80(948): 588-601.
28. Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T (2009). Tick-borne encephalitis virus - a review of an emerging zoonosis. J. Gen. Virol. 90(Pt 8): 1781-1794.
29. Marchevsky RS, Freire MS, Coutinho ES, Galler R (2003). Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology, 316(1): 55-63.
30. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS (2007). A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196(12): 1732-1740.
31. Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD (2008). Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine, 26(2): 153-157.
32. Mason PW, Shustov AV, Frolov I (2006). Production and characterization of vaccines based on flaviviruses defective in replication. Virology, 351(2): 432-443.
33. Monath TP (2001). Yellow fever: an update. Lancet Infect. Dis. 1(1): 11-20.
34. Mukhopadhyay S, Zhang W, Gabler S, Chipman PR, Strauss EG, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG (2006). Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses. Structure, 14(1): 63-73.
35. Nalca A, Fellows PF, Whitehouse CA (2003). Vaccines and animal models for arboviral encephalitides. Antiviral Res. 60(3): 153-174.
36. Plesner AM, Ronne T (1997). Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine, 15(11): 1239-1243.
37. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM (2003). Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology, 314(1): 190-195.
38. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981). Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59(6): 895-900.
39. Pugachev KV, Guirakhoo F, Monath TP (2005). New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin. Infect. Dis. 18(5): 387-394.
40. Rabablert J, Yoksan S (2009). Attenuated D2 16681-PDK53 vaccine: defining humoral and cell-mediated immunity. Curr. Pharm. Des. 15(11): 1203-1211.
41. Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garcon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL (2005). An evaluation of dengue type-2 inactivated, recombinant subunit, and liveattenuated vaccine candidates in the rhesus macaque model. Vaccine, 23(35): 4442-4452.
42. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, Esteves K (1996). Yellow fever: a decade of reemergence. JAMA 276(14): 1157-1162.
43. Roukens AH, Visser LG (2008). Yellow fever vaccine: past, present and future. Expert Opin. Biol. Ther. 8(11): 1787-1795.
44. Sellards A, Langret J (1932). Vaccination de l'homme contre la fievre jaune. C R Acad Sci 194:1609-1611.
45. Solomon T, Mallewa M (2001). Dengue and other emerging flaviviruses. J. Infect. 42(2): 104-115.
46. Souza MC, Freire MS, Schulze EA, Gaspar LP, Castilho LR (2009). Production of yellow fever virus in microcarrier-based Vero cell cultures. Vaccine, 27(46): 6420-6423.
47. Suzuki R, Winkelmann ER, Mason PW (2009). Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol. 83(4): 1870-1880.
48. Theiler M, Smith HH (2000). The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65: 787-800 (1937). Rev. Med. Virol. 10(1): 6-16; discussion 13-15.
49. Watts DM, Tesh RB, Siirin M, Rosa AT, Newman PC, Clements DE, Ogata S, Coller BA, Weeks-Levy C, Lieberman MM (2007). Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine, 25(15): 2913-2918.
50. Webster DP, Farrar J, Rowland-Jones S (2009). Progress towards a dengue vaccine. Lancet Infect. Dis. 9(11): 678-687.
51. Widman DG, Frolov I, Mason PW (2008). Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv. Virus Res. 72: 77-126.
52. Wilder-Smith A, Deen JL (2008). Dengue vaccines for travelers. Expert Rev. Vaccines, 7(5): 569-578.
53. Williams KL, Zompi S, Beatty PR, Harris E (2009). A mouse model for studying dengue virus pathogenesis and immune response. Ann. N. Y. Acad. Sci. 1171 Suppl 1: E12-23.
54. Yamshchikov G, Borisevich V, Seregin A, Chaporgina E, Mishina M, Mishin V, Kwok CW, Yamshchikov V (2004). An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology, 330(1): 304-312.